Drugs / Hu1928-Hu20BB-Long
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05797233 | Aug 2023 → Dec 2028 expected | B-cell chronic lymphocytic leukemia | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hu1928-Hu20BB-Long | “T -cells expressing this CAR construct, called Hu1928-Hu20BB-Long, can specifically recognize CD19 and CD20-expressing target cells in vitro and eradicate CD19 or...” NCT05797233 ↗ |
| Action | Deplete | “modified to carry genes (chimeric antigen receptor, or CAR T cells) to kill cancer cells.” NCT05797233 ↗ |
| Modality | Cell therapy | “T-cells obtained by leukapheresis will be genetically modified to express the Hu1928- Hu20BB-Long CAR construct.” NCT05797233 ↗ |
| Route | Intravenous | “Their T cells, now modified, will be infused back into their bloodstream through a tube placed in a large vein.” NCT05797233 ↗ |